Impact of Stage-Specific Guideline Concordant Treatment in Small Cell Lung Cancer in Victoria, Australia

Small cell lung cancer (SCLC) accounts for 15% of all Australian lung cancer cases. In Victoria, patients with SCLC have a median survival time of 7.2 months. Guidelines are available to clinicians for the treatment of limited-stage (LS) and extensive-stage (ES) SCLC. The utilisation of treatment guidelines aim to improve evidence-based management of patients with SCLC and limit unwarranted variation in treatment. Clinical adherence to these guidelines is likely to lead to an improvement in survival.